Advances in research of pept1-targeted prodrug

Asian Journal of Pharmaceutical Sciences

Volumn 7, Issue 2, 2012, Pages 110-122

  Cao, Feng ^a   Gao, Yahan ^a   Ping, Qineng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Peptide transporter 1; Peptidomimetics; Targeted prodrug

Indexed keywords

ACICLOVIR; ALENDRONIC ACID; AMIDE; CYTARABINE; DIDANOSINE; EGLUMETAD; ESTER; FLOXURIDINE; GANCICLOVIR; GEMCITABINE; MIDODRINE; OLEANOLIC ACID; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; PEPTIDOMIMETIC AGENT; PRODRUG; TALAGLUMETAD; VALACICLOVIR; VALGANCICLOVIR;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; BLOOD EYE BARRIER; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; HERPES SIMPLEX; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; INTESTINE MUCOSA PERMEABILITY; MEMBRANE POTENTIAL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84871408725     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976, 455: 152-62.
2. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010, 62: 1-96.
3. Lee EJ, Lean CB, Limenta LM. Role of membrane transporters in the safety profile of drugs. Expert Opin Drug Metab Toxicol. 2009, 5: 1369-1383.
4. Ware JA. Membrane transporters in drug discovery and development: A new mechanistic ADME era. Mol Pharm. 2006, 3: 1-2.
5. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid and cholesterol transporters: function and regulation. Pharmacol Rev. 2010, 62: 1-96.
6. Zhang EY, Knipp GT, Ekins S, et al. Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev. 2002, 34: 709-750.
7. Brandsch M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol. 2009, 5: 887-905.
8. Rais R, Fletcher S, Polli JE. Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). J Pharm Sci. 2011, 100: 1184-1195.
9. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512[(±)-1- ([(a-Isobutanoyloxyethoxy) carbonyl] aminomethyl)- 1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters. J Pharmacol Exp Ther. 2004, 311: 315-323.
10. Kato K, Shirasaka Y, Kuraoka E, et al. Intestinal Absorption Mechanism of Tebipenem Pivoxil, a Novel Oral Carbapenem: Involvement of Human OATP Family in Apical Membrane Transport. Mol Pharm. 2010, 7(5): 1747-1756.
11. Gynther M, Ropponen J, Laine K, et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J Med Chem. 2009, 52: 3348-3353.
12. Luo S, Wang Z, Patel M, et al. Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir. Int J Pharm. 2011, 414: 77-85.
13. Peura L, Malmioja K, Laine K, et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol Pharm. 2011, 8: 1857-1866.
14. Knutter I, Wollesky C, Kottra G, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008, 327: 432-441.
15. Watanabe K, Sawano T, Jinriki T, et al. Studies on intestinal absorption of sulpiride (3): intestinal absorption of sulpiride in rats. Biol Pharm Bull. 2004, 27: 77-81.
16. +/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999, 16: 55-61.
17. Sun J, Dahan A, Amidon GL. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem. 2010, 53: 624-32.
18. Varghese Gupta S, Gupta D, Sun J, et al. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm. 2011, 8: 2358-2267.
19. Han H, de Vrueh RL, Rhie JK, et al. L. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998, 15: 1154-1159.
20. Adibi SA. Intestinal transport of dipeptides in man: relative importance of hydrolysis and intact absorption. J Clin Invest. 1971, 50: 2266-2275.
21. Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004, 447: 610-618.
22. Ganapathy V, Leibach FH. Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit. Studies with L-carnosine and glycyl-L-proline. J Biol Chem. 1983, 258: 14189-14192.
23. Terada T, Sawada K, Saito H, et al. Functional characteristics of basolateral peptide transporter in the human intestinal cell line Caco-2. Am J Physiol. 1999, 276: 1435-1441.
24. Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol Sci. 2002, 23: 434-440.
25. Daniel H, Herget M. Cellular and molecular mechanisms of renal peptide transport. Am J Physiol. 1997, 273: F1-F8.
26. Sai Y, Tamai I, Sumikawa H, et al. Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of beta-lactam antibiotics. FEBS Lett. 1996, 392: 25-29.
27. Groneberg DA, Doring F, Eynott PR, et al. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol Gastrointest Liver Physiol. 2001, 281: G697-G704.
28. Smith DE, Pavlova A, Berger UV, et al. Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm Res. 1998, 15: 1244-1249.
29. Knutter I, Rubio-Aliaga I, Boll M, et al. H-peptide cotransport in the human bile duct epithelium cell line SKChA- 1. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283: G222-G229.
30. Agu R, Cowley E, Shao D, et al. Proton-coupled oligopeptide transporter (POT) family expression in human nasal epithelium and their drug transport potential. Mol Pharm. 2011, 8: 664-672.
31. Englund G, Rorsman F, Rönnblom A, et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006, 29: 269-277.
32. Ford D, Howard A, Hirst BH. Expression of the peptide transporter hPepT1 in human colon: a potential route for colonic protein nitrogen and drug absorption. Histochem Cell Biol. 2003, 119: 37-43.
33. Terada T, Shimada Y, Pan X, et al. Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochem Pharmacol. 2005, 70: 1756-1763.
34. Zhang T, Xiang CD, Gale D, et al. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos. 2008, 36: 1300-1307.
35. Naruhashi K, Sai Y, Tamai I, et al. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm Res. 2002, 19: 1417-1423.
36. Groneberg DA, Eynott PR, Doring F, et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax. 2002, 57: 55-60.
37. Groneberg DA, Doring F, Nickolaus M, et al. Renal assimilation of short chain peptides: visualization of tubular peptide uptake. Pharm Res. 2002, 19: 1209-1214.
38. Groneberg DA, Doring F, Nickolaus M, et al. Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia. Neurosci Lett. 2001, 304: 181-184.
39. Groneberg DA, Doring F, Theis S, et al. Peptide transport in the mammary gland: expression and distribution of PEPT2 mRNA and protein. Am J Physiol Endocrinol Metab. 2002, 282: E1172-E1179.
40. Newstead S, Drew D, Cameron AD, et al. Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2. EMBO J. 2011, 30(2): 417-26.
41. Covitz KM, Amidon GL, Sade'e H. Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry. 1998, 37: 15214-15221.
42. Newstead S. Towards a structural understanding of drug and peptide transport within the proton-dependent oligopeptide transporter (POT) family. Biochem Soc Trans. 2011, 39: 1353-1358.
43. Fei YJ, Kanai Y, Nussberger S, et al. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 1994, 368, 563-566.
44. Brodin B, Nielsen CU, Steffansen B, et al. Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1. Pharmacol Toxicol. 2002, 90: 285-96.
45. Tamura KC, Lee P, Smith PL, et al. Borchardt: Metabolism, uptake, and transepithelial transport of the stereoisomers of Val-Val-Val in the human intestinal cell line, Caco-2. Pharm Res. 1996, 113: 1663-1667.
46. Brandsch M, Knütter I, Leibach FH. The intestinal H+/ peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004, 21: 53-60.
47. Meredith D, Temple CS, Guha N, et al. Bailey: Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. Eur J Biochem. 2000, 267: 3723-3728.
48. Matthews DM. Mechanisms of peptide transport. Beitr Infusionther Klin Ernahr. 1987, 17: 6-53.
49. Do ring F, Walter J, Will J, et al. Daniel: Deltaaminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest. 1998a, 101: 2761-2767.
50. Doring F, Will J, Amasheh S, et al. Daniel: Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J Biol Chem. 1998b, 273: 23211-23218.
51. Bailey PD, Boyd CA, Bronk JR, et al. How to Make Drugs Orally Active: A Substrate Template for Peptide Transporter PepT1. Angew Chem Int Ed Engl. 2000, 39(3): 505-508.
52. Brandsch M, Knütter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008, 60(5): 543-85.
53. Eriksson AH, Varma MV, Perkins EJ, et al. The Intestinal Absorption of a Prodrug of the mGlu2/3 Receptor Agonist LY354740 is Mediated by PEPT1: In Situ Rat Intestinal Perfusion Studies. J Pharm Sci. 2010, 99(3): 1574-81.
54. Bueno AB, Collado I, de Dios A, et al. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J Med Chem. 2005, 48: 5305-5320.
55. Tsuda M, Terada T, Irie M, et al. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006, 318: 455-460.
56. Ezra A, Hoffman A, Breuer E, et al. A Peptide Prodrug Approach for Improving Bisphosphonate Oral Absorption. J Med Chem. 2000, 43(20): 3641-52.
57. Guo A, Hu P, Balimane PV, et al. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999, 289: 448-454.
58. Perry CM, Faulds, Valaciclovir D. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996, 52: 754-772.
59. Cocohoba JM, McNicholl, Valganciclovir IR. An advance in cytomegalovirus therapeutics. Ann Pharmacother. 2002, 36: 1075-1079.
60. Reusser P. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin Investig Drugs. 2001, 10: 1745-1753.
61. Sun Y, Sun J, Shi S, et al. Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-β-Darabinofuranosylcytosine. Mol Pharm. 2009, 6: 315-325.
62. Yan Z, Sun J, Chang Y, et al. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics. Mol Pharm. 2011, 8: 319-329.
63. Cao F, Jia J, Yin Z, et al. Ethylene glycol-linked amino acid diester prodrugs of oleanolic acid for PepT1- mediated transport: synthesis, intestinal permeability and pharmacokinetics. Mol Pharm. 2012, http://dx.doi.org/10.1021/mp200447r.
64. Johnson JT, Mattiuz EL, Chay SH, et al. The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. Drug Metab Dispos. 2002, 30: 27-33.
65. Perkins EJ, Abraham T. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2S)- (2-amino)propionyl] aminobicyclo[3.1.0.] hexen-2,6- dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity. Drug Metab Dispos. 2007, 35: 1903-1909.
66. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester prodrugs. J Pharm Sci. 2006, 95: 1177-1195.
67. Zhang Q, Liu Q, Wu J, et al. PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. Eur J Pharmacol. 2009, 612: 9-14.
68. Ogihara T, Kano T, Wagatsuma T, et al. Oseltamivir (Tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos. 2009, 37: 1676-1681.
69. Vergin H, Kikuta C, Mascher H, et al. Pharmacokinetics and bioavailability of different formulations of acyclovir. Arzneimittelforschung. 1995, 45: 508-515.
70. Beauchamp LM, Orr GF, De Miranda P, et al. Amino acid ester prodrugs of acyclovir. Antivir Chem Chemother. 1992, 3:157-164.
71. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995, 39: 2759-2764.
72. Beutner KR. Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antivir Res. 1995, 28: 281-290.
73. Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res. 1998, 15:1382-1386.
74. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV seropositive subjects. J Clin Pharmacol. 1999, 39: 800-804.
75. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000, 44: 2811-2815.
76. Sugawara M, Huang W, Fei YJ, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000, 89: 781-789.
77. Jain R, Majumdar S, Nashed Y, et al. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol Pharm. 2004, 1: 290-299.
78. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev. 1999, 39: 211-238.
79. Jain R, Duvvuri S, Kansara V, et al. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int J Pharm. 2007, 336: 233-240.
80. Jain R, Agarwal S, Mandava NK, et al. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux. Int J Pharm. 2008, 362: 44-51.
81. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006, 58: 1136-1163.
82. Anand BS, Mitra AK. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm Res. 2002, 19: 1194-1202.
83. Majumdar S, Nashed YE, Patel K, et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocular Pharmacol Ther. 2005, 21: 463-474.
84. Majumdar S, Kansara V, Mitra AK. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J Ocul Pharmacol Ther. 2006, 22: 231-41.
85. Atluri H, Anand BS, Patel J, et al. Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp Eye Res. 2004, 78, 815-822.
86. Talluri RS, Samanta SK, Gaudana R, et al. Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int J Pharm. 2008, 361: 118-124.
87. Talluri RS, Gaudana R, Hariharan S, et al. Pharmacokinetics of stereoisomeric dipeptide prodrugs of acyclovir following intravenous and oral administrations in rats: A study involving in vivo corneal uptake of acyclovir following oral dosing. Ophthalmology and Eye Diseases. 2009, 1: 21-31.
88. Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011, 63: 659-70.
89. Landowski CP, Vig BS, Song X, et al. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther. 2005, 4: 659-667.
90. Nakanishi T, Tamai I, Sai Y, et al. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res. 1997, 57: 4118-4122.
91. Mitsuoka K, Miyoshi S, Kato Y, et al. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/ peptide transporter. J Nucl Med. 2008, 49: 615-622.
92. Nakanishi T, Tamai I, Takaki A, et al. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer. 2000, 88: 274-280.
93. Landowski CP, Vig BS, Song X, et al. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther. 2005, 4: 659-667.
94. Tsume Y, Hilfinger JM, Amidon GL. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008, 5: 717-727.
95. Gallop MA, Peng G, Woiwode TF. Gemcitabine prodrugs, pharmaceuticals compositions and uses thereof. US7803785, 2010-09-28.
96. Foley D, Bailey P, Pieri M, et al. Targeting ketone drugs towards transport by the intestinal peptide transporter, PepT1. Org Biomol Chem. 2009, 7: 1064-1067.
97. Bailey PD. Drug delivery system. US20080139670 [P], 2008-06-12.
98. Foley D, Pieri M, Pettecrew R, et al. The in vitro transport of model thiodipeptide prodrugs designed to target the intestinal oligopeptide transporter, PepT1. Org Biomol Chem. 2009, 7: 3652-6.
99. Ihara T, Tsujikawa T, Fujiyama Y, et al. Regulation of PepT1 peptide transporter expression in the rat small intestine under malnourished conditions. Digestion. 2000, 61: 59-67.